Millennium Management’s Aimmune Therapeutics AIMT Stock Holding History

Millennium Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-35,000	Closed	-$1.17M	–	4821
2019 Q4	$1.17M	Buy	+35,000	New	+$978K	﹤0.01%	2936
2018 Q2	–	Sell	-100,000	Closed	-$3.18M	–	4354
2018 Q1	$3.18M	Buy	+100,000	New	+$3.52M	﹤0.01%	2065
2017 Q4	–	Sell	-102,300	Closed	-$2.54M	–	4219
2017 Q3	$2.54M	Buy	+102,300	New	+$2.21M	﹤0.01%	2039

Millennium Management's AIMT Position: Q4 2020 in Review

Millennium Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 464,696 shares — an estimated $16K sold.

Millennium Management first reported a position in AIMT in Q1 2018 and held it in 7 quarters. The position peaked at $6.22M in Q1 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Millennium Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Millennium Management sold 464,696 Aimmune Therapeutics shares in Q4 2020, an estimated $16K.
Millennium Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 7 quarters.
Millennium Management's Aimmune Therapeutics position peaked at $6.22M in Q1 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Millennium Management's 13F filing for Q4 2020, filed 16 Feb 2021.